Analy­sis shows The Med­i­cines Com­pa­ny/Al­ny­lam drug in­clisir­an safe for re­nal­ly-im­paired pa­tients

About a week af­ter long-term Phase II da­ta on The Med­i­cines Com­pa­ny’s $MD­CO Al­ny­lam $AL­NY-part­nered twice-year­ly cho­les­terol fight­er, in­clisir­an, was in­di­cat­ed as safe and ef­fec­tive as the ap­proved once-month­ly Repatha and Pralu­ent, its man­u­fac­tur­ers pre­sent­ed da­ta at the Eu­ro­pean Ath­er­o­scle­ro­sis So­ci­ety Con­gress from two tri­als in­volv­ing re­nal­ly-im­paired pa­tients.

Al­to­geth­er da­ta from 279 pa­tients across the two tri­als showed that pa­tients with dif­fer­ent lev­els of re­nal func­tion achieved con­sis­tent re­duc­tions in low-den­si­ty lipopro­tein cho­les­terol (LDL-C), or “bad” cho­les­terol with in­clisir­an treat­ment, and did not re­quire dose ad­just­ment, The Med­i­cines Co said over the week­end.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER